AUTHOR=Cai Wenting , Zhang Ruobin , Yao Yao , Wu Qiuhui , Zhang Jinping 

TITLE=Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials

JOURNAL=Frontiers in Public Health

VOLUME=12

YEAR=2024

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2024.1277113

DOI=10.3389/fpubh.2024.1277113

ISSN=2296-2565

ABSTRACT=<sec id="sec1"><title>Objective</title><p>To systematically evaluate the efficacy and safety of a new hypoglycemic drug, tirzepatide, for treating obesity based on indicators such as BMI, waist circumference, and body weight.</p></sec><sec id="sec2"><title>Methods</title><p>A search formula was written using search terms such as “tirzepatide,” “overweight,” and “obesity.” A comprehensive search was conducted on databases such as PubMed, Cochrane Library, Embase, and Web of Science using a computer. Random controlled trial (RCT) literature was selected based on inclusion and exclusion criteria. After extracting the data, literature bias risk assessment and meta-analysis were conducted using RevMan 5.4 software. The search deadline is from the establishment of each database to May 2023.</p></sec><sec id="sec3"><title>Results</title><p>A total of 12 randomized controlled trials were included, with a total of 11,758 patients. Meta analysis results showed that compared with the glucagon like peptide-1 receptor agonist (GLP-1 RAs), placebo and insulin groups, tirzepatide could significantly reduce the BMI (body mass index) of patients [MD = −1.71, 95% CI (−2.46, −0.95), <italic>p</italic> &lt; 0.00001], [MD = −3.99, 95% CI (−3.69, −2.45), <italic>p</italic> &lt; 0.00001], [MD = −4.02, 95% CI (−4.72, −3.31), <italic>p</italic> &lt; 00.00001]. In terms of decreasing waist circumference, tirzepatide has a more significant advantage [MD = −4.08, 95% CI (−5.77, −2.39), <italic>p</italic> &lt; 0.00001], [MD = −7.71, 95% CI (−10.17, −5.25), <italic>p</italic> &lt; 0.00001], [MD = −9.15, 95% CI (−10.02, −8.29), <italic>p</italic> &lt; 0.00001]. In the analysis of body weight, tirzepatide showed a more significant reduction effect compared to the control group [MD = −5.65, 95% CI (−7.47, −3.82), <italic>p</italic> &lt; 0.001], [MD = −10.06, 95% CI (−12.86, −7.25), <italic>p</italic> &lt; 0.001], [MD = −10.63, 95% CI (−12.42, −8.84), <italic>p</italic> &lt; 0.001]. In comparison with placebo, tirzepatide had a prominent advantage in weight loss ≥20% and ≥25% [RR = 30.43, 95% CI (19.56, 47.33), <italic>p</italic> &lt; 0.00001], [RR = 37.25, 95% CI (26.03, 53.30), <italic>p</italic> &lt; 0.00001]. Subgroup analysis showed a dose-dependent therapeutic effect. In terms of safety, compared with the placebo and insulin groups, the incidence of gastrointestinal adverse reactions was markedly higher in the tirzepatide group, slightly higher to the GLP-1 RAs group. The hypoglycemic (&lt;70 mg/dL) risk of tirzepatide was slightly higher to that of placebo and GLP-1 RAs, but significantly lower than that of the insulin group [RR = 0.46, 95% CI (0.36, 0.58), <italic>p</italic> &lt; 0.001]. The incidence of other adverse events, including pancreatitis, cholecystitis, major adverse cardiovascular events-4, hypersensitivity reactions, and neoplasms did not show significant statistical differences compared to the control group (<italic>p</italic> &gt; 0.05).</p></sec><sec id="sec4"><title>Conclusion</title><p>Tirzepatide, as a weight loss drug, significantly reduces BMI, waist circumference and body weight while gastrointestinal adverse reactions need to be vigilant. Overall, its efficacy is significant and its safety is high.</p></sec>